Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OAK study of AZD5363 tablet versus capsule and food effect in advanced solid malignancies
NL-OMON40390Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of capivasertib in Nonhematologic neoplasms (2 arms), sponsored by AstraZeneca. Primary endpoints: Pharmacokinetic comparison of tablet versus capsule and Food effect on pharmacokinetic exposure. Started Dec 2013; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON40390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40390.